OXiGENE (OXGN) Announces Phase 2 Ovarian Cancer Trial of ZYBRESTAT(R) Plus Bevacizumab Achieves Important Interim Safety Objective
8/6/2012 9:15:37 AM
SOUTH SAN FRANCISCO, Calif., Aug. 6, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today that the randomized Phase 2 study evaluating the combination of ZYBRESTAT® (fosbretabulin tromethamine or CA4P) and bevacizumab to treat patients with advanced platinum-sensitive ovarian cancer has achieved an important safety objective in a scheduled interim toxicity analysis, and is expected to continue to full enrollment. The Phase 2 study (GOG 186I) is being conducted by the Gynecologic Oncology Group (GOG) under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). The fosbretabulin tromethamine is being provided to CTEP under a Cooperative Research and Development Agreement (CRADA) with OXiGENE and the bevacizumab is being provided under a CRADA with Genentech, Inc.
comments powered by